BioCentury
ARTICLE | Clinical News

Mologen's lefitolimod misses in extension for HIV infection

August 11, 2017 3:44 PM UTC

Mologen AG (Xetra:MGN) reported data from 12 patients with chronic HIV-1 infection on antiretroviral therapy (ART) in a 24-week extension of the open-label, Danish Phase Ib/IIa TEACH trial showing that twice-weekly 60 mg subcutaneous lefitolimod (MGN1703) missed the primary endpoint. Specifically, Mologen said lefitolimod “had no detectable effects" on the size of the viral reservoir in peripheral blood.

The company added the extension to TEACH after data showed that twice-weekly subcutaneous lefitolimod for 4 weeks increased HIV-1 transcription and enhanced cytotoxic NK cell activation in TEACH’s 15 patients...